Navigation Links
BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea
Date:11/10/2008

CMP Will Purchase at Least 227 HyperQ(TM) Systems During the Term of the

Agreement

TEL AVIV, Israel, November 10 /PRNewswire-FirstCall/ -- BSP (Biological Signal Processing Ltd.) (http://www.bsp.co.il/), an Israeli company that develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease (IHD), announced that it has signed an exclusive distribution agreement with CMP Trading Co., Ltd to distribute HyperQ(TM) Stress System in South Korea.

CMP has undertaken to purchase at least 227 HyperQ(TM) systems through the end of 2011. The number of systems may change subject to the date of receipt of regulatory approval from the Korean Food and Drug Administration, an essential step towards the marketing and use of the system in Korea. BSP estimates that the price per system to CMP will vary from about US$ 15,000 to roughly US$ 20,000, dependent on the system configuration. Accordingly, the total revenues resulting from this agreement are expected to be a minimum of US$ 3,400,000.

Mr. Chan Min Park, President of CMP Trading said, "We are extremely encouraged by the very positive response to the HyperQ technology from medical centers. We believe that BSP's product can change the way ischemic heart diseases are being diagnosed."

"This second distribution agreement consolidates BSP's position in the Asia-Pacific markets. We view Korea as one of the most receptive countries to innovative technologies," said Dr. Amir Beker, BSP's founder and CEO.

Dr. Beker adds, "We are grateful for the ongoing vote of confidence in our HyperQ technology by leading physicians in Asia and the United States. We plan to continue with the installment of our HyperQ system into top medical centers."

This week, BSP is introducing its new version of the HyperQ(TM) System at the 2008 conference of the American Heart Association in
'/>"/>

SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
3. Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography
4. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
5. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
6. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
7. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
10. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
11. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... Industry Analysis, Size, Share, Growth, Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a ... RNA) into cells. This technology helps the cells to ... metabolism by affecting the nuclear genes. The transfection technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Fla., Dec. 6, 2010 Investigators report no evidence of ... in a gene therapy trial using a vector under development ... (University College London) to correct the inherited bleeding disorder. ... test, with low and intermediate doses of the vector expected ...
... 6, 2010 See video from Novartis at: ... Novartis announced 24-month data showing that Tasigna® (nilotinib) ... of adult patients with newly diagnosed Philadelphia chromosome-positive ... These new data, from the first Phase III ...
... Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: ... follow up results from the Company,s pivotal phase III ... Company,s recent Marketing Authorization Application (the "MAA") currently under ... The end-of-study results showed continued improvement in the trial,s ...
Cached Biology Technology:Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 3Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 3New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 5New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 6
(Date:7/10/2014)... -- Smart technology emphasis grows in biometrics sector ... NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: AAPL ), Visa Inc. (NYSE: ... (OTCQB: NXTD) a biometric authentication company focused on the growing ... of 30 second spots on CNBC for its next generation ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market ... Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application ... & Finance), and Geography - Global Trends & Forecasts ... Fingerprint Sensors Market is projected to cross $14.35 Billion ... from 2014 to 2020. Browse more than ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with atrial fibrillation are often treated with anticoagulants to ... dose and patients have to have their blood tested ... of Gothenburg and Chalmers University of Technology have now ... risk assessments. Atrial fibrillation, or irregular heartbeat, ...
... day of competition in London, a team of four ... emerged as the winners of this year,s Biotechnology Young ... Biotechnology Young Entrepreneurs Scheme (YES) competition are Ben Owens, ... University of Oxford. The team pitched their ...
... industry is booming more and more solar modules ... plants are increasingly feeding power into the grid. Multi-junction ... can achieve efficiencies of up to 43 percent - ... crystalline silicon. The trick: they consist of several semi-conductor ...
Cached Biology News:New method for safer dosing of anticoagulants 2Winning early-career researchers excel in entrepreneurship 2Winning early-career researchers excel in entrepreneurship 3Fraunhofer researchers receive the Franco-German Business Award 2011 2
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
Biology Products: